Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer

Naganawa Y, Ishiguro H, Kuwabara Y, et al: Decreased expression of FBXW7 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Exp Ther Med. 1:841–846. 2010.PubMed/NCBI

Ando T, Ishiguro H, Kuwabara Y, et al: Expression of ACP6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep. 15:1551–1555. 2006.PubMed/NCBI

Japanese Society for Esophageal Disease. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th edition. Kanehara Publ. Co.; Tokyo: 1999

Ando T, Ishiguro H, Kuwabara Y, et al: Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Eso. 21:15–20. 2007.

Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 6:1322–1327. 2000.

Nishimura G, Terada I, Kobayashi T, et al: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep. 9:479–482. 2002.PubMed/NCBI

Oguri T, Achiwa H, Bessho Y, et al: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 49:345–351. 2005. View Article : Google Scholar : PubMed/NCBI

Terashima M, Irunoda T, Fujiwara H, et al: Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res. 22:761–768. 2002.PubMed/NCBI

Shirota Y, Ichikawa W, Uetake H, Yamada H, Nihei Z and Sugihara K: Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. Ann Sur Oncol. 9:599–603. 2002. View Article : Google Scholar

Suda Y, Kuwashima Y, Tanaka Y, Uchida K, Sakamoto H, Hashiguchi Y and Sekine T: Expression of thymidylate synthase and thymidine phosphorylase in recurrence and survival rates of advanced gastric cancer. Gastric Cancer. 2:165–172. 1999. View Article : Google Scholar : PubMed/NCBI

Tanaka K, Otake K, Mohri Y, et al: Clinical significance of the gene expression profile in residual tumor cells after neoadjuvant chemoradiotherapy for esophageal cancer. Oncol Rep. 21:1489–1494. 2009. View Article : Google Scholar : PubMed/NCBI

Brücher BLDM, Keller G, Werner M, et al: Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis. 24:69–77. 2009.PubMed/NCBI

Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 30A:1517–1522. 1994. View Article : Google Scholar : PubMed/NCBI

Danenberg KD, Salonga D, Park JM, et al: Dihydropyrimidine dehydrogenase and thymidylate synthase gene expression identify a high percentage of colorectal tumors responding to 5-fluorouracil. Proc Am Soc Clin Oncol. 17:258–262. 1998.

Ichikawa W, Takahasi T, Suto K, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer. 112:967–973. 2004. View Article : Google Scholar : PubMed/NCBI